Jannink I, van Diest P J, Baak J P
Department of Pathology, Free University Hospital, Amsterdam, The Netherlands.
Hum Pathol. 1995 Oct;26(10):1086-92. doi: 10.1016/0046-8177(95)90270-8.
Proliferation markers and especially the Mitotic Activity Index (MAI) are strong and reproducible prognosticators in invasive breast cancer. Traditionally, the MAI has been defined as the total number of mitoses counted in 10 consecutive high-power fields (objective, x40; numeric aperture, .75; field diameter, 450 microns), in the most cellular area at the periphery of the tumor, with the subjectively highest mitotic activity. No correction for epithelial percentage or cellularity was applied. This study investigates whether the prognostic value of mitotic activity could be improved by a random sampling procedure or correction for percentage of epithelium present. For this purpose the prognostic value of four methods used to assess mitotic activity in invasive breast cancer was compared in 4-microns-thick hematoxylin-eosin (H&E)-stained sections of 186 primary invasive breast cancer patients. These were the MAI, the random MAI (rMAI), the Mitosis per Volume (M/V) Index, and the random M/V Index (rM/V Index). The rMAI was defined as the total number of mitotic figures counted in 10 random fields through the whole outlined tumor at x400 magnification. A correction for the volume percentage of epithelium assessed with stereology yielded the M/V Index and the rM/V Index, respectively. The results of all four methods showed moderate to high correlations. Univariate survival analysis (Kaplan-Meier curves; Mantel-Cox test) confirmed that all four methods had a strong prognostic value (P < .001). The MAI, however, produced the best results (Mantel-Cox value, 17.1). Multivariate analysis showed that all four methods had additional prognostic value to tumor size and lymph node status. The M/V Index provided most additional prognostic information, followed by the MAI. Assessment of rMAI took 20 to 30 minutes on average, about two times longer than MAI. The correction for volume percentage of epithelium took about 10 minutes longer for both methods than the uncorrected methods. In conclusion, the rMAI gives an impression of the mitotic activity through the whole tumor, with almost similar prognostic value as the traditional MAI, especially when correcting for percentage of epithelium. Nevertheless, the MAI is still to be preferred, because the assessment is easy to apply and less time consuming.
增殖标志物,尤其是有丝分裂活性指数(MAI),在浸润性乳腺癌中是强有力且可重复的预后指标。传统上,MAI被定义为在肿瘤周边细胞最丰富区域、主观上有丝分裂活性最高的连续10个高倍视野(物镜,×40;数值孔径,0.75;视野直径,450微米)中计数的有丝分裂总数。未对上皮细胞百分比或细胞密度进行校正。本研究调查通过随机抽样程序或对存在的上皮细胞百分比进行校正,是否能提高有丝分裂活性的预后价值。为此,在186例原发性浸润性乳腺癌患者的4微米厚苏木精-伊红(H&E)染色切片中,比较了用于评估浸润性乳腺癌有丝分裂活性的四种方法的预后价值。这四种方法分别是MAI、随机MAI(rMAI)、每体积有丝分裂数(M/V)指数和随机M/V指数(rM/V指数)。rMAI定义为在×400放大倍数下通过整个勾勒出的肿瘤随机选取的10个视野中计数的有丝分裂象总数。用体视学评估上皮细胞体积百分比进行校正后分别得出M/V指数和rM/V指数。所有四种方法的结果显示出中度到高度的相关性。单因素生存分析(Kaplan-Meier曲线;Mantel-Cox检验)证实所有四种方法都有很强的预后价值(P < 0.001)。然而,MAI产生的结果最佳(Mantel-Cox值,17.1)。多因素分析表明,所有四种方法对肿瘤大小和淋巴结状态都有额外的预后价值。M/V指数提供的额外预后信息最多,其次是MAI。评估rMAI平均需要20到30分钟,比MAI长约两倍。两种方法对上皮细胞体积百分比进行校正比对未校正方法所需时间长约10分钟。总之,rMAI能反映整个肿瘤的有丝分裂活性,预后价值与传统MAI几乎相似,尤其是在对上皮细胞百分比进行校正时。然而,MAI仍是首选,因为其评估易于应用且耗时较少。